China Pharma (CPHI) Competitors

$1.24 +0.24 (+24.45%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+0.73%)

As of 05/14/2026 08:00 PM Eastern

CPHI vs. MOLN, PLYX, HURA, OGI, and PLX

Should you buy China Pharma stock or one of its competitors? MarketBeat compares China Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China Pharma include Molecular Partners (MOLN), Polaryx Therapeutics (PLYX), TuHURA Biosciences (HURA), Organigram Global (OGI), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry.

How does China Pharma compare to Molecular Partners?

Molecular Partners (NASDAQ:MOLN) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

China Pharma has lower revenue, but higher earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	27.44	-$74.41M	-$1.99	N/A
China Pharma	$4.14M	12.12	-$3.08M	-$0.75	N/A

Molecular Partners has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, China Pharma has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Molecular Partners presently has a consensus price target of $8.38, indicating a potential upside of 118.10%. Given Molecular Partners' stronger consensus rating and higher probable upside, equities research analysts plainly believe Molecular Partners is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Molecular Partners has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
China Pharma	-85.56%	-63.93%	-31.42%

26.6% of Molecular Partners shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Molecular Partners had 3 more articles in the media than China Pharma. MarketBeat recorded 4 mentions for Molecular Partners and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 beat Molecular Partners' score of -0.28 indicating that China Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Molecular Partners beats China Pharma on 9 of the 16 factors compared between the two stocks.

How does China Pharma compare to Polaryx Therapeutics?

China Pharma (NYSE:CPHI) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Polaryx Therapeutics has lower revenue, but higher earnings than China Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$4.14M	12.12	-$3.08M	-$0.75	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 193.26%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Polaryx Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Polaryx Therapeutics' return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Polaryx Therapeutics had 4 more articles in the media than China Pharma. MarketBeat recorded 5 mentions for Polaryx Therapeutics and 1 mentions for China Pharma. Polaryx Therapeutics' average media sentiment score of 0.91 beat China Pharma's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Polaryx Therapeutics beats China Pharma on 8 of the 9 factors compared between the two stocks.

How does China Pharma compare to TuHURA Biosciences?

China Pharma (NYSE:CPHI) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, TuHURA Biosciences had 2 more articles in the media than China Pharma. MarketBeat recorded 3 mentions for TuHURA Biosciences and 1 mentions for China Pharma. TuHURA Biosciences' average media sentiment score of 0.65 beat China Pharma's score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.6% of TuHURA Biosciences shares are owned by institutional investors. 6.4% of China Pharma shares are owned by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

China Pharma has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

China Pharma has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$4.14M	12.12	-$3.08M	-$0.75	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.63	N/A

TuHURA Biosciences has a consensus price target of $9.00, indicating a potential upside of 258.57%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

TuHURA Biosciences has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
TuHURA Biosciences	N/A	-182.40%	-117.49%

Summary

TuHURA Biosciences beats China Pharma on 8 of the 15 factors compared between the two stocks.

How does China Pharma compare to Organigram Global?

China Pharma (NYSE:CPHI) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Organigram Global has a net margin of -9.22% compared to China Pharma's net margin of -85.56%. Organigram Global's return on equity of -13.41% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Organigram Global	-9.22%	-13.41%	-9.09%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Organigram Global had 11 more articles in the media than China Pharma. MarketBeat recorded 12 mentions for Organigram Global and 1 mentions for China Pharma. Organigram Global's average media sentiment score of 0.18 beat China Pharma's score of 0.00 indicating that Organigram Global is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organigram Global	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

China Pharma has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Organigram Global has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

34.6% of Organigram Global shares are owned by institutional investors. 6.4% of China Pharma shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

China Pharma has higher earnings, but lower revenue than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$4.14M	12.12	-$3.08M	-$0.75	N/A
Organigram Global	$185.07M	0.83	-$17.70M	-$0.13	N/A

Summary

Organigram Global beats China Pharma on 11 of the 15 factors compared between the two stocks.

How does China Pharma compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Protalix BioTherapeutics has a net margin of -21.03% compared to China Pharma's net margin of -85.56%. Protalix BioTherapeutics' return on equity of -30.89% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
China Pharma	-85.56%	-63.93%	-31.42%

Protalix BioTherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 500.00%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Protalix BioTherapeutics had 6 more articles in the media than China Pharma. MarketBeat recorded 7 mentions for Protalix BioTherapeutics and 1 mentions for China Pharma. Protalix BioTherapeutics' average media sentiment score of 0.20 beat China Pharma's score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, China Pharma has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 6.4% of China Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Protalix BioTherapeutics has higher revenue and earnings than China Pharma. China Pharma is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$52.74M	3.06	$8.31M	$0.18	11.11
China Pharma	$4.14M	12.12	-$3.08M	-$0.75	N/A

Summary

Protalix BioTherapeutics beats China Pharma on 13 of the 16 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPHI vs. The Competition

Export

Metric	China Pharma	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$40.38M	$935.59M	$6.34B	$22.90B
Dividend Yield	N/A	4.84%	2.80%	4.09%
P/E Ratio	-1.65	1.48	20.89	30.78
Price / Sales	12.12	115.81	549.88	95.02
Price / Cash	N/A	20.07	43.26	25.31
Price / Book	1.77	8.11	9.93	4.67
Net Income	-$3.08M	-$3.91M	$3.55B	$1.06B
7 Day Performance	137.09%	9.43%	1.70%	-0.89%
1 Month Performance	93.15%	76.62%	0.49%	1.42%
1 Year Performance	-47.23%	140.55%	39.41%	24.64%

China Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPHI China Pharma	N/A	$1.24 +24.4%	N/A	-44.1%	$40.38M	$4.14M	N/A	250	News Coverage Gap Down High Trading Volume
MOLN Molecular Partners	2.5326 of 5 stars	$3.84 -4.0%	$8.38 +118.1%	-1.8%	$161.50M	$5.65M	N/A	180	Earnings Report
PLYX Polaryx Therapeutics	3.5685 of 5 stars	$3.41 +1.2%	$10.00 +193.3%	N/A	$160.37M	N/A	N/A	11	News Coverage Gap Up
HURA TuHURA Biosciences	2.7023 of 5 stars	$2.51 flat	$9.00 +258.6%	-35.5%	$159.84M	N/A	N/A	N/A	Upcoming Earnings
OGI Organigram Global	1.0312 of 5 stars	$1.09 -2.2%	N/A	-10.7%	$156.96M	$185.07M	N/A	1,139	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CPHI) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China Pharma (CPHI) Competitors

CPHI vs. MOLN, PLYX, HURA, OGI, and PLX

How does China Pharma compare to Molecular Partners?

Summary

How does China Pharma compare to Polaryx Therapeutics?

Summary

How does China Pharma compare to TuHURA Biosciences?

Summary

How does China Pharma compare to Organigram Global?

Summary

How does China Pharma compare to Protalix BioTherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China Pharma (CPHI) Competitors

CPHI vs. MOLN, PLYX, HURA, OGI, and PLX

How does China Pharma compare to Molecular Partners?

Which has preferable earnings and valuation, MOLN or CPHI?

Which has more risk and volatility, MOLN or CPHI?

Do analysts prefer MOLN or CPHI?

Is MOLN or CPHI more profitable?

Do institutionals and insiders believe in MOLN or CPHI?

Does the media prefer MOLN or CPHI?

Summary

How does China Pharma compare to Polaryx Therapeutics?

Which has higher valuation and earnings, CPHI or PLYX?

Do analysts recommend CPHI or PLYX?

Is CPHI or PLYX more profitable?

Does the media prefer CPHI or PLYX?

Summary

How does China Pharma compare to TuHURA Biosciences?

Does the media favor CPHI or HURA?

Do institutionals & insiders have more ownership in CPHI or HURA?

Which has more volatility & risk, CPHI or HURA?

Which has better valuation & earnings, CPHI or HURA?

Do analysts recommend CPHI or HURA?

Is CPHI or HURA more profitable?

Summary

How does China Pharma compare to Organigram Global?

Is CPHI or OGI more profitable?

Do analysts recommend CPHI or OGI?

Does the media favor CPHI or OGI?

Which has more volatility & risk, CPHI or OGI?

Do institutionals & insiders have more ownership in CPHI or OGI?

Which has better valuation & earnings, CPHI or OGI?

Summary

How does China Pharma compare to Protalix BioTherapeutics?

Is PLX or CPHI more profitable?

Do analysts recommend PLX or CPHI?

Does the media refer more to PLX or CPHI?

Which has more risk & volatility, PLX or CPHI?

Do insiders and institutionals have more ownership in PLX or CPHI?

Which has preferable valuation and earnings, PLX or CPHI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools